July 2 (Reuters) - AstraZeneca has entered into a deal worth up to $1.77 billion with CSPC Pharmaceutical Group to discover ...

Detailed price information for Cspc Pharm Group Ltd Ord (CHJTF) from The Globe and Mail including charting and trades.

AstraZeneca has returned to China's CSPC Pharma to fill its R&D pipeline, reaching a new agreement to develop drugs for ...

Detailed price information for Cspc Pharm Group Ltd Ord (CHJTF) from The Globe and Mail including charting and trades.

AstraZeneca (AZN) has reached a partnership worth up to $1.77B with CSPC ‌Pharmaceutical Group (CSPCY) to develop and ...

AstraZeneca will pay CSPC $30 million upfront. The Chinese company will also be eligible to receive up to $540 million in ...

AstraZeneca has added another piece to its sprawling interface with CSPC Pharmaceutical, paying the Chinese biotech $30 million upfront to jointly discover and develop two kidney disease drug ...

AstraZeneca (LSE: AZN) and CSPC Pharmaceutical (1093: HK) have added renal disease to a growing list of areas covered by their research tie-ups, with a new collaboration to develop small nucleic acid ...

The U.S. FDA investigates anesthesia complications in patients with Venezuelan ancestry. AstraZeneca partners with CSPC for ...

AstraZeneca signs a deal worth up to $1.77 billion with China’s CSPC Pharmaceutical to develop experimental siRNA therapies for chronic kidney diseases.